A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe

Status Terminated

Clinical Trial Summary

A two-component therapeutic consisting of FCX-013 and veledimex for the treatment of localized scleroderma (or morphea). The first component, FCX-013, is autologous human fibroblasts genetically-modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen. FCX-013 is designed to be injected under the skin at the location of the fibrotic lesions where the genetically-modified fibroblast cells will produce MMP-1 to break down excess collagen accumulation. With the FCX-013 therapy, the patient will take an oral compound (Veledimex) to induce MMP-1 protein expression from the injected cells. Once the fibrosis is resolved, the patient will stop taking the oral compound which will stop further MMP-1 production from the injected cells. FCX-013 plus veledimex is being developed in anticipation of improving skin function in patients by resolving fibrotic lesions and normalizing dermal collagen production

Clinical Trial Description

Castle Creek is developing a two-component therapeutic product for the treatment of moderate to severe localized scleroderma (morphea). The first component is FCX-013, an autologous genetically modified human dermal fibroblast (GM-HDFs) cell product that is genetically modified with a lentiviral vector (LV) to express human matrix metalloproteinase 1 (MMP1). MMP1 is also known as interstitial collagenase or fibroblast collagenase and is an enzyme that under normal physiological conditions breaks down the extracellular matrix. Specifically, MMP1 breaks down interstitial collagens, types I, II and III. In addition, the FCX-013 cells are also transduced with genetic constructs that encode the RheoSwitch Therapeutic System® (RTS®) an inducible promotor system that in the presence of a small molecule activator ligand controls expression of the MMP1 gene. The RTS® is activated to express MMP1 by the oral administration of the small molecule component. The purpose of this open-label single arm Phase 1/2 study is to investigate the safety and effectiveness of FCX-013 plus veledimex. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03740724
Study type	Interventional
Source	Castle Creek Biosciences, LLC.
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	December 18, 2019
Completion date	April 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02798055` - Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
Completed	`NCT01959815` - Novel Screening Strategies for Scleroderma PAH
Completed	`NCT03274076` - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Phase 1/Phase 2
Completed	`NCT02915835` - Riociguat in Scleroderma Associated Digital Ulcers	Phase 2
Active, not recruiting	`NCT01895244` - Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis	Phase 2
Completed	`NCT00930683` - A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma	Phase 1
Completed	`NCT00883129` - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)	Phase 2
Completed	`NCT00074568` - Scleroderma Registry
Recruiting	`NCT04797286` - Sildenafil for Early Pulmonary Vascular Disease in Scleroderma	Phase 2
Completed	`NCT03222492` - Brentuximab Vedotin for Systemic Sclerosis	Phase 1/Phase 2
Completed	`NCT03207997` - MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients	N/A
Recruiting	`NCT04464434` - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis	Phase 4
Recruiting	`NCT04246528` - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)	N/A
Completed	`NCT05080738` - Upper Extremity Home Exercises in Patients With Scleroderma	N/A
Recruiting	`NCT03726398` - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH	Phase 2/Phase 3
Recruiting	`NCT05085444` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma	Early Phase 1
Completed	`NCT02062125` - Calcinosis in a Single-Center Scleroderma Population
Completed	`NCT04588714` - Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention	N/A
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT02835196` - Optical Elastography of Systemic Sclerosis Skin

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms